Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.

Date publication

septembre 2017

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Pivot X, Verma S, Fallowfield L, Müller V, Lichinitser M, Jenkins V, Sánchez Muñoz A, Machackova Z, Osborne S, Gligorov J,

Lien Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28963915

Résumé

To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166).

Mots clés

Breast cancer, HER2/neu, Herceptin, Patient preference, Subcutaneous, Trastuzumab

Référence

Eur. J. Cancer. 2017 Sep;86:82-90